Microvena's Trap VFS
This article was originally published in The Gray Sheet
Executive Summary
Vascular filtration system for use during angioplasty and stenting procedures in saphenous vein bypass grafts is anticipated to debut in Europe in the fourth quarter following CE mark approval in July. Phase I multi-center randomized U.S. trials commenced in June, and enrollment should be complete by the end of year, the firm says. In contrast to distal protection systems that use occlusion balloons, the device's self-expanding nitinol filter, placed downstream of the target lesion, captures debris while allowing blood to continue to flow uninterrupted, according to the company. Microvena expects to launch the Trap in the U.S. by late 2001 or early 2002
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.